Remavir 100mg 30 capsules — Made in Latvia — Free Delivery

Pharmacological properties

Pharmacodynamics. Rimantadine hydrochloride - a derivative of amantadine, has a pronounced antiviral activity. Effective against various influenza type a viruses, and also has an antitoxic effect against influenza caused by type b virus. rimantadine inhibits viral replication in the early stages of the cycle by disrupting the formation of the viral envelope. genetic studies have established that a specific protein of the virion m2 gene is of great importance in the antiviral action of rimantadine against influenza a virus. in vitro, rimantadine inhibits the replication of all three antigenic subtypes (h1n1, h2n2, h3n3) of the influenza virus identified in humans. rimantadine does not affect the immunogenic properties of inactivated influenza a vaccine.

Rimantadine is also effective against arboviruses, which are the causative agents of tick-borne encephalitis.

Pharmacokinetics. After a single or multiple administration of the preparation by patients of different age groups, the correlation between the concentration of rimantadine in blood plasma and its antiviral activity has not been established.

Absorption. After oral administration, the preparation is almost completely absorbed.

Distribution. After a single oral administration of the preparation Remavir at a dose of 100 mg, the average plasma concentration is 74 ng / ml (range from 45 to 138 ng / ml) - in healthy adult patients aged 20–44 years, it is reached after 5–7 hours.

About 40% of the preparation Remavir binds to blood plasma proteins, mainly albumin. T1 / 2 of one dose in this study group averages 25 hours, and in patients aged 71–79 years - an average of 32 hours.

Metabolism. Remavir is extensively metabolized in the liver by hydroxylation, conjugation and glucuronidation.

Excretion. Three hydroxylated metabolites were identified in blood plasma. These and other metabolites make up 74 ± 10% of a single 200 mg dose. The preparation is excreted in the form of metabolites in the urine within 72 hours. Less than 25% of the preparation is excreted in the urine unchanged.

In renal failure, the concentration of Remavir metabolites in the blood plasma increases. The dose of rimantadine should be reduced by 50% if creatinine clearance is 5–29 ml / min. Chronic kidney disease does not significantly affect the pharmacokinetics of rimantadine.

The pharmacokinetics of the preparation in children is close to the pharmacokinetics in adults.

Indications

Pills. early treatment of illness caused by influenza type a viruses in adults and children over the age of 10. prevention of influenza type a during an epidemic in adults and children over the age of 10 years.

Capsules. Early treatment of illness caused by influenza A viruses in adults and children over the age of 10. Prevention of influenza type A during an epidemic in adults and children over the age of 10.

Powder. Prevention and treatment of influenza A at an early stage of the disease in children over the age of 1 year.

Application

The tablets are taken orally after meals with water. the use of remavir should be started immediately after the first symptoms of influenza appear. the therapeutic effect is more pronounced if the use of the preparation is started within the first 48 hours after the onset of the first symptoms of influenza.

Treatment for influenza: adults and children over the age of 10 years - 100 mg (2 tablets) 2 times a day.

Before using the preparation in children, be sure to consult a doctor.

Elderly patients (65 years old) - 100 mg (2 tablets) once a day.

The duration of the course of treatment is 5 days.

Prevention of influenza: adults and children over the age of 10 years - 100 mg (2 tablets) 2 times a day.

Elderly patients or with a high risk of complications - 100 mg (2 tablets) 1 time per day.

The use of the preparation is recommended from the beginning of an influenza epidemic and during an epidemic, but not more than 2 weeks.

Capsules are taken orally, after meals, with water. The capsule must not be chewed.

The use of Remavir should be started as early as possible, immediately after the first symptoms of influenza appear. The therapeutic effect is more pronounced if the preparation is started within the first 48 hours after the first symptoms of influenza appear.

Treatment for influenza: adults and children over the age of 10 years - 100 mg 2 times a day.

Before using the preparation in children, be sure to consult a doctor.

Elderly patients (65 years) - 100 mg once a day.

The duration of the course of treatment is 5 days.

Prevention of influenza: adults and children over the age of 10 years - 100 mg 2 times a day.

Elderly patients or with a high risk of complications - 100 mg once a day.

The use of the preparation is recommended from the beginning of an influenza epidemic and during an epidemic, but not more than 2 weeks.

Powder. If symptoms of influenza appear (fever, muscle pain, headache, eye pain), you should start using Remavir 20 mg as soon as possible. The therapeutic effect is more pronounced if the preparation is started within the first 48 hours from the onset of the disease. Dissolve the contents of the sachet in ½ cup of warm water and take inside after meals.

Treatment. Children aged 1 to 10 years are prescribed 5 mg / kg of body weight per day in 2-3 doses, but not more than 100 mg Remavir (5 sachets) per day. Children aged 11 to 14 years - 140-160 mg of the preparation (7-8 sachets) per day in several doses. Children over the age of 14 are prescribed doses for adults (use the preparation Remavir tablets at a dose of 50 mg). The duration of the course of treatment is 5 days.

Contraindications

Tablets and capsules. hypersensitivity to rimantadine, derivatives of the adamantane group and excipients of the preparation. acute and chronic diseases of the liver and kidneys. thyrotoxicosis.

Powder. Hypersensitivity to rimantadine or auxiliary components of the preparation, acute liver disease, acute and chronic kidney disease, thyrotoxicosis. The preparation contains aspartame - a source of phenylalanine. Its use is contraindicated in patients with phenylketonuria.

Side effects

The preparation is usually well tolerated.

Classification of adverse reactions by frequency of development: very often (≥1 / 10); often (≥1 / 100 to 1/10); infrequently (≥1 / 1000 to 1/100); rarely (≥1 / 10,000 to 1/1000); very rare (1/10 000).

From the digestive tract: often - dyspepsia (nausea, vomiting); infrequently - abdominal pain, diarrhea, indigestion, dry mouth, anorexia.

From the nervous system: often - insomnia; rarely - impaired concentration, dizziness, headache, fatigue, tremors, hallucinations, convulsions, confusion, ataxia (impaired coordination of movements), drowsiness, increased excitability, depression, euphoria, hyperkinesis (spontaneous movements), change / loss of taste, parosmia.

From the side of the heart: infrequently - palpitations, heart failure, edema, cardiac conduction disturbances (blockade), tachycardia.

From the side of the vessels: infrequently - hypertension, cerebrovascular disorders, fainting.

On the part of the genitals and mammary glands: infrequently - galactorrhea.

From the vestibular apparatus and the organ of hearing: infrequently - noise / ringing in the ears.

From the respiratory system, chest and mediastinal organs: infrequently - cough, shortness of breath, bronchospasm.

Skin and subcutaneous tissue disorders: infrequently - rash, itching, urticaria.

From the immune system: infrequently - pallor of the skin, hypersensitivity reactions are possible, including skin rashes, itching, urticaria.

General disorders: infrequently - asthenia (weakness), exacerbation of concomitant chronic diseases, increased fatigue.

Usually, side effects disappear after you stop taking the preparation.

Special instructions

Remavir is prescribed with caution to patients with gastrointestinal diseases, impaired liver function, severe heart disease and cardiac arrhythmias, and the elderly. in these cases, a reduction in the dose of the preparation is recommended.

With indications of a history of epilepsy and anticonvulsant therapy while using rimantadine, the risk of developing an epileptic seizure increases. In this case, the dose of rimantadine is reduced to 100 mg / day. If an attack develops, the preparation is discontinued.

The appearance of viruses resistant to the preparation is possible.

Tablets and capsules contain lactose, therefore, patients with rare hereditary forms of galactose intolerance, lactase deficiency or glucose-galactose malabsorption syndrome should not use this preparation.

During pregnancy and breastfeeding. Remavir penetrates the placental barrier and into breast milk, therefore, the use of the preparation during this period is contraindicated.

Children. Tablets and capsules can be used in children over the age of 10.

Powder. The efficacy and safety of the preparation in children under the age of 1 year have not been established, therefore, the preparation in this dosage form is not used in children aged 1 to 14 years.

The ability to influence the reaction rate when driving and working with other mechanisms. When using the preparation, you should refrain from driving vehicles and working with potentially dangerous mechanisms.

Interactions

Paracetamol and acetylsalicylic acid reduce the effectiveness of Remavir.

Remavir reduces the effectiveness of antiepileptic preparations.

Remavir enhances the aphrodisiac effect of caffeine.

Cimetidine may enhance the effect of Remavir.

During the period of treatment, one should refrain from drinking alcoholic beverages, since this may cause unwanted side effects from the central nervous system.

Overdose

In cases of overdose - symptomatic therapy to maintain vital body functions.

There is information about a case of poisoning with a chemical analogue - amantadine.

Symptoms: agitation, hallucinations, heart rhythm disturbances, fever, chills, increased sweating, arrhythmia, hypesthesia, increased lacrimation, dysphagia, constipation, increased urination, stomatitis, eye pain.

Treatment: preparation withdrawal, gastric lavage, administration of physiostigmine to children at a dose of 0.5 mg, if necessary, repeated administration, but not more than 2 mg / h. Rimantadine and amantadine are not excreted by hemodialysis.

Storage conditions

In a dry place at a temperature not exceeding 25 ° C.